Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Abstract

In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).

Keywords

MedicineCytokine release syndromeInternal medicineBone marrowGastroenterologySurgeryAcute lymphocytic leukemiaLeukemiaCancerChimeric antigen receptorLymphoblastic LeukemiaImmunotherapy

Affiliated Institutions

Related Publications

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Intraepithelial CD8<sup>+</sup>tumor-infiltrating lymphocytes and a high CD8<sup>+</sup>/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

Eiichi Sato , Sara H. Olson , Jiyoung Ahn +15 more

In a recent report, [Zhang et al. (2003) N. Engl. J. Med. 348, 203–213], the presence of CD3 + tumor-infiltrating lymphocytes (TILs) was found to correlate with improved surviva...

2005 Proceedings of the National Academy o... 2340 citations

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda , Laura Q.M. Chow , Elizabeth Claire Dees +9 more

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...

2016 Journal of Clinical Oncology 1427 citations

Cancer immunotherapy using checkpoint blockade

Antoni Ribas , Jedd D. Wolchok

The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...

2018 Science 6236 citations

Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

R B Sleight , Peter Sleight , Sarah Parish +3 more

17,187 patients entering 417 hospitals up to 24 hours (median 5 hours) after the onset of suspected acute myocardial infarction were randomised, with placebo control, between: (...

1988 PubMed 2873 citations

Publication Info

Year: 2018
Type: article
Volume: 378
Issue: 5
Pages: 449-459
Citations: 2545
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2545

OpenAlex

Cite This

APA Style

                            
                                
                                    Jae H. Park, 
                                
                                    Isabelle Rivière, 
                                
                                    Mithat Gönen
                                
                                et al.
                            
                            (2018). 
                            Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. 
                            New England Journal of Medicine
                            , 378
                            (5)
                            , 449-459.
                            https://doi.org/10.1056/nejmoa1709919
                        

Identifiers

DOI: 10.1056/nejmoa1709919